Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 18, 2018

Teva reports positive results for fremanezumab in phase IIIb migraine trial

Teva Pharmaceutical Industries said that the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients has yielded positive results.

Teva reports positive results for fremanezumab in phase IIIb migraine trial